Loading…
Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice
As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patient...
Saved in:
| Published in: | Future oncology (London, England) England), 2019-08, Vol.15 (24s), p.7-12 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3 |
| container_end_page | 12 |
| container_issue | 24s |
| container_start_page | 7 |
| container_title | Future oncology (London, England) |
| container_volume | 15 |
| creator | Marina, Michela Serra, Maria Francesca Rio, Paolo Del Ceresini, Graziano |
| description | As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patients treated with lenvatinib for radioiodine-refractory differentiated thyroid cancer in whom the QTc interval was long monitored through a weekly 12-lead ECG registration. Overall, the maximum QTc increase above baseline was 3 and 31 ms in the first and second patient, respectively. QTc interval did not reach the toxicity value for drug withdrawal in either of the patients. These data may provide further information on cardiac safety profile of lenvatinib in a real-life practice. |
| doi_str_mv | 10.2217/fon-2019-0096 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2275264265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2473448414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhgdRbK0u3UrAjZtoksl8uZPSqlAoQl2HTHKiKTPJ9SRTuP-mP9Vze6sLwVUS8uR9w3ma5rUU75WSw4eQE1dCTlyIqX_SnMpBaz62Qj6lvR4m3veTPmlelHIrhB7aTjxvTlqp5dhN4rS5v7izy2ZrzInlwOpPYN9uHIupAtIN8xvG9IMtkO4ISnFmFcHWFVIliKH1McfsYwKOENC6mnHPfAwBkJhoK3hK3WOOnjmbHOBHhrDLWAsLmNeHSopc-BIDMLdQiaPi3SErOnjZPAt2KfDqcT1rvl9e3Jx_4VfXn7-ef7riTktR-TC0s5NSSPCdCKGzuh-D9QFGq0A450WrQM8TeCUm3wY_zh04OQTRayW9a8-ad8fcHeZfG5Rq1lgcLItNkLdilBo6RWzfEfr2H_Q2b5jod0bRhLUetdRE8SPlMJdCwzE7jKvFvZHCHNQZUmcO6sxBHfFvHlO3eQX_l_7jioDpCIStbgjFRaBxmuOJXkRHFv4T_hsVSqyL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473448414</pqid></control><display><type>article</type><title>Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice</title><source>PubMed Central</source><creator>Marina, Michela ; Serra, Maria Francesca ; Rio, Paolo Del ; Ceresini, Graziano</creator><creatorcontrib>Marina, Michela ; Serra, Maria Francesca ; Rio, Paolo Del ; Ceresini, Graziano</creatorcontrib><description>As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patients treated with lenvatinib for radioiodine-refractory differentiated thyroid cancer in whom the QTc interval was long monitored through a weekly 12-lead ECG registration. Overall, the maximum QTc increase above baseline was 3 and 31 ms in the first and second patient, respectively. QTc interval did not reach the toxicity value for drug withdrawal in either of the patients. These data may provide further information on cardiac safety profile of lenvatinib in a real-life practice.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2019-0096</identifier><identifier>PMID: 31418590</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Blood pressure ; Cancer therapies ; case report ; Case reports ; Combined Modality Therapy ; Drug dosages ; Drug withdrawal ; ECG ; Electrocardiography ; Fentanyl ; Heart rate ; Heart Ventricles - drug effects ; Heart Ventricles - physiopathology ; Humans ; Hypertension ; Iodine Radioisotopes - administration & dosage ; lenvatinib ; Lymphatic system ; Male ; Medical imaging ; Metastasis ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - radiotherapy ; Neoplasm Recurrence, Local - surgery ; Patients ; Phenylurea Compounds - administration & dosage ; Phenylurea Compounds - adverse effects ; Potassium ; Progression-Free Survival ; Quinolines - administration & dosage ; Quinolines - adverse effects ; Thyroid cancer ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - radiotherapy ; Thyroid Neoplasms - surgery</subject><ispartof>Future oncology (London, England), 2019-08, Vol.15 (24s), p.7-12</ispartof><rights>2019 Graziano Ceresini</rights><rights>Copyright Future Medicine Ltd Aug 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3</citedby><cites>FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31418590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marina, Michela</creatorcontrib><creatorcontrib>Serra, Maria Francesca</creatorcontrib><creatorcontrib>Rio, Paolo Del</creatorcontrib><creatorcontrib>Ceresini, Graziano</creatorcontrib><title>Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patients treated with lenvatinib for radioiodine-refractory differentiated thyroid cancer in whom the QTc interval was long monitored through a weekly 12-lead ECG registration. Overall, the maximum QTc increase above baseline was 3 and 31 ms in the first and second patient, respectively. QTc interval did not reach the toxicity value for drug withdrawal in either of the patients. These data may provide further information on cardiac safety profile of lenvatinib in a real-life practice.</description><subject>Blood pressure</subject><subject>Cancer therapies</subject><subject>case report</subject><subject>Case reports</subject><subject>Combined Modality Therapy</subject><subject>Drug dosages</subject><subject>Drug withdrawal</subject><subject>ECG</subject><subject>Electrocardiography</subject><subject>Fentanyl</subject><subject>Heart rate</subject><subject>Heart Ventricles - drug effects</subject><subject>Heart Ventricles - physiopathology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Iodine Radioisotopes - administration & dosage</subject><subject>lenvatinib</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - radiotherapy</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Patients</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Potassium</subject><subject>Progression-Free Survival</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - adverse effects</subject><subject>Thyroid cancer</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyroid Neoplasms - surgery</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kU1rFTEUhgdRbK0u3UrAjZtoksl8uZPSqlAoQl2HTHKiKTPJ9SRTuP-mP9Vze6sLwVUS8uR9w3ma5rUU75WSw4eQE1dCTlyIqX_SnMpBaz62Qj6lvR4m3veTPmlelHIrhB7aTjxvTlqp5dhN4rS5v7izy2ZrzInlwOpPYN9uHIupAtIN8xvG9IMtkO4ISnFmFcHWFVIliKH1McfsYwKOENC6mnHPfAwBkJhoK3hK3WOOnjmbHOBHhrDLWAsLmNeHSopc-BIDMLdQiaPi3SErOnjZPAt2KfDqcT1rvl9e3Jx_4VfXn7-ef7riTktR-TC0s5NSSPCdCKGzuh-D9QFGq0A450WrQM8TeCUm3wY_zh04OQTRayW9a8-ad8fcHeZfG5Rq1lgcLItNkLdilBo6RWzfEfr2H_Q2b5jod0bRhLUetdRE8SPlMJdCwzE7jKvFvZHCHNQZUmcO6sxBHfFvHlO3eQX_l_7jioDpCIStbgjFRaBxmuOJXkRHFv4T_hsVSqyL</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Marina, Michela</creator><creator>Serra, Maria Francesca</creator><creator>Rio, Paolo Del</creator><creator>Ceresini, Graziano</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190801</creationdate><title>Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice</title><author>Marina, Michela ; Serra, Maria Francesca ; Rio, Paolo Del ; Ceresini, Graziano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Blood pressure</topic><topic>Cancer therapies</topic><topic>case report</topic><topic>Case reports</topic><topic>Combined Modality Therapy</topic><topic>Drug dosages</topic><topic>Drug withdrawal</topic><topic>ECG</topic><topic>Electrocardiography</topic><topic>Fentanyl</topic><topic>Heart rate</topic><topic>Heart Ventricles - drug effects</topic><topic>Heart Ventricles - physiopathology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Iodine Radioisotopes - administration & dosage</topic><topic>lenvatinib</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - radiotherapy</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Patients</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Potassium</topic><topic>Progression-Free Survival</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - adverse effects</topic><topic>Thyroid cancer</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyroid Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marina, Michela</creatorcontrib><creatorcontrib>Serra, Maria Francesca</creatorcontrib><creatorcontrib>Rio, Paolo Del</creatorcontrib><creatorcontrib>Ceresini, Graziano</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marina, Michela</au><au>Serra, Maria Francesca</au><au>Rio, Paolo Del</au><au>Ceresini, Graziano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>15</volume><issue>24s</issue><spage>7</spage><epage>12</epage><pages>7-12</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>As for other tyrosine kinase inhibitors, a prolongation of ECG-recorded QTc intervals may be observed during lenvatinib treatment; a warning on this phenomenon has been stated. However, methods and frequency of ECG recordings have seldom been reported in this context. We present two cases of patients treated with lenvatinib for radioiodine-refractory differentiated thyroid cancer in whom the QTc interval was long monitored through a weekly 12-lead ECG registration. Overall, the maximum QTc increase above baseline was 3 and 31 ms in the first and second patient, respectively. QTc interval did not reach the toxicity value for drug withdrawal in either of the patients. These data may provide further information on cardiac safety profile of lenvatinib in a real-life practice.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31418590</pmid><doi>10.2217/fon-2019-0096</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2019-08, Vol.15 (24s), p.7-12 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2275264265 |
| source | PubMed Central |
| subjects | Blood pressure Cancer therapies case report Case reports Combined Modality Therapy Drug dosages Drug withdrawal ECG Electrocardiography Fentanyl Heart rate Heart Ventricles - drug effects Heart Ventricles - physiopathology Humans Hypertension Iodine Radioisotopes - administration & dosage lenvatinib Lymphatic system Male Medical imaging Metastasis Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - radiotherapy Neoplasm Recurrence, Local - surgery Patients Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Potassium Progression-Free Survival Quinolines - administration & dosage Quinolines - adverse effects Thyroid cancer Thyroid Neoplasms - drug therapy Thyroid Neoplasms - pathology Thyroid Neoplasms - radiotherapy Thyroid Neoplasms - surgery |
| title | Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20QTc%20interval%20during%20lenvatinib%20treatment%20in%20radioiodine-refractory%20differentiated%20thyroid%20cancer:%20reports%20from%20the%20real-life%20clinical%20practice&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Marina,%20Michela&rft.date=2019-08-01&rft.volume=15&rft.issue=24s&rft.spage=7&rft.epage=12&rft.pages=7-12&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2019-0096&rft_dat=%3Cproquest_cross%3E2473448414%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c410t-773bc1101ed50ff5a468fadfe8a2e0ccd032e4b9ed209d3fd8b5ec17f06421dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2473448414&rft_id=info:pmid/31418590&rfr_iscdi=true |